Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil.
Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil
Br J Sports Med. 2023 Dec;57(23):1516-1521. doi: 10.1136/bjsports-2022-106403. Epub 2023 Aug 24.
To investigate the effects of pharmacological and non-pharmacological therapies on pain intensity and disability for plantar fasciitis.
Systematic review of randomised controlled trials (RCTs).
AMED, MEDLINE, PEDro, Cochrane, SPORTDiscus, CINAHL, EMBASE and PsycINFO without language or date restrictions up to 3 February 2023.
RCTs that evaluated the efficacy of any pharmacological and non-pharmacological therapies compared with control (placebo, sham, waiting list or no intervention) on pain intensity and disability in people with plantar fasciitis. Two reviewers independently screened eligible trials, extracted data, assessed the methodological quality of included trials and assessed the certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluations framework. Mean differences (MDs) with 95% CIs were reported.
Seventeen different therapies investigated in 28 trials were included in the quantitative analysis. For non-pharmacological therapies, moderate certainty evidence showed short-term effects of customised orthoses on pain intensity when compared with control (MD of -12.0 points (95% CI -17.1 to -7.0) on a 0-100 scale). Low certainty evidence showed short-term effects of taping on pain intensity (-21.3 (95% CI -38.6 to -4.0)). Long-term effects and effects on disability are still uncertain. For pharmacological therapies, low to very low quality evidence from few trials with small samples was inconclusive and supports that high-quality trials are needed.
Moderate-quality and low-quality evidence demonstrates customised orthoses and taping, respectively, reduce pain intensity in the short term in patients with plantar fasciitis.
CRD42021224416.
研究药物和非药物疗法对足底筋膜炎疼痛强度和功能障碍的影响。
随机对照试验的系统评价。
AMED、MEDLINE、PEDro、Cochrane、SPORTDiscus、CINAHL、EMBASE 和 PsycINFO，无语言和日期限制，检索时间截至 2023 年 2 月 3 日。
评估任何药物和非药物疗法与对照组（安慰剂、假治疗、等待名单或无干预）相比在足底筋膜炎患者疼痛强度和功能障碍方面的疗效的随机对照试验。两名审查员独立筛选合格试验，提取数据，评估纳入试验的方法学质量，并使用推荐、评估、开发和评估（Grading of Recommendations, Assessment, Development and Evaluations，GRADE）框架评估证据的确定性。报告均值差（Mean Differences，MDs）及其 95%置信区间（Confidence Intervals，CI）。
纳入 28 项试验的 17 种不同治疗方法进行了定量分析。对于非药物疗法，定制矫形器在短期治疗中对疼痛强度的影响具有中等确定性证据（0-100 量表上的 MD 值为-12.0 分（95%CI -17.1 至 -7.0））。短期治疗中贴扎对疼痛强度的影响具有低确定性证据（-21.3（95%CI -38.6 至 -4.0））。长期疗效和对功能障碍的影响仍不确定。对于药物疗法，来自少数小型样本试验的低质量到极低质量证据尚无定论，支持需要高质量的试验。
中等质量和低质量证据表明，定制矫形器和贴扎分别在短期治疗中减轻足底筋膜炎患者的疼痛强度。
PROSPERO 注册号：CRD42021224416。
